S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSE:AIM

AIM ImmunoTech (AIM) Stock Price, News & Analysis

$0.47
+0.03 (+6.80%)
(As of 03/28/2024 ET)
Today's Range
$0.45
$0.50
50-Day Range
$0.33
$0.45
52-Week Range
$0.32
$0.75
Volume
422,677 shs
Average Volume
177,478 shs
Market Capitalization
$23.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AIM stock logo

About AIM ImmunoTech Stock (NYSE:AIM)

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM Stock Price History

AIM Stock News Headlines

Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
PRISM MarketView Marks World Cancer Day
See More Headlines
Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2023
Today
3/28/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Employees
22
Year Founded
1990

Profitability

Net Income
$-19,440,000.00
Net Margins
-10,764.25%
Pretax Margin
-10,764.25%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
$0.79 per share

Miscellaneous

Free Float
48,832,000
Market Cap
$23.00 million
Optionable
Not Optionable
Beta
-0.13

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Thomas K. Equels Esq.Mr. Thomas K. Equels Esq. (Age 71)
    J.D., M.S., Executive Vice Chairman, CEO & President
    Comp: $1.24M
  • Mr. Robert Dickey IV (Age 68)
    M.B.A., Chief Financial Officer
    Comp: $60.98k
  • Mr. Peter W. Rodino III (Age 73)
    Esq., J.D., COO, Executive Director of Governmental Relations, General Counsel & Secretary
    Comp: $630k
  • Ann Marie E. Coverly
    Director of Administration & Human Resources and Deputy Investor Relations Coordinator
  • Dr. Carol A. Smith (Age 73)
    Chief Manufacturing Officer & Deputy Chief Scientific Officer
    Comp: $170.77k
  • Dr. Christopher McAleer Ph.D.
    Scientific Officer
  • Dr. Ralph Christopher Cavalli Ph.D. (Age 66)
    Vice President of QC & Manufacturing
    Comp: $234.79k
  • Jodie Pelz
    Director of Finance

AIM Stock Analysis - Frequently Asked Questions

How have AIM shares performed in 2024?

AIM ImmunoTech's stock was trading at $0.4399 at the start of the year. Since then, AIM shares have increased by 7.1% and is now trading at $0.4710.
View the best growth stocks for 2024 here
.

When is AIM ImmunoTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our AIM earnings forecast
.

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) posted its quarterly earnings data on Wednesday, November, 15th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.05. The business had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 67.33% and a negative net margin of 10,764.25%.

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX).

How do I buy shares of AIM ImmunoTech?

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AIM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners